期刊文献+

维持性血液透析患者血管平滑肌细胞p53的表达与血管钙化的关系 被引量:4

Relationship Between Expression of p53 in Vascular Smooth Muscle Cells and Vascular Calcification in Maintenance Hemodialysis Patients
暂未订购
导出
摘要 目的探讨维持性血液透析患者血管平滑肌细胞p53的表达与血管钙化的关系。方法选择慢性肾脏疾病5期维持性血液透析患者17例(透析时间在1年以上),均为自体桡动脉-头静脉内瘘作为透析通路的患者,因自体动静脉内瘘失功拟重建血管通路。在动静脉内瘘重建过程中,取失功动静脉内瘘动脉段作为实验组标本,同龄人群(取材于尸体肾供者)腹主动脉作为对照组。以von Kossa染色法对血管钙化进行定性检测,甲酚酞络合酮化学法对血管钙化进行定量检测,磷酸苯二钠法测定血管组织碱性磷酸酶活性,Western blotting检测血管组织p53蛋白水平,并对血管钙含量和碱性磷酸酶活性与p53的表达进行相关性分析。结果维持性血液透析患者桡动脉血管平滑肌细胞p53的表达(p53/β-actin灰度比为0.81)显著低于同龄人群腹主动脉血管平滑肌细胞p53的表达(p53/β-actin灰度比为1.72),而血管平滑肌细胞钙含量和碱性磷酸酶活性分别较同龄人群腹主动脉血管平滑肌细胞增加69%和105%(P均<0.01)。相关性分析发现,p53的表达与血管平滑肌细胞钙含量和碱性磷酸酶活性均成显著负相关(r=-0.77和r=-0.86,P均<0.01)。结论在5期慢性肾脏疾病维持性血液透析患者中血管钙化广泛存在,血管钙化伴随着血管平滑肌细胞p53蛋白表达的显著下降,这一现象提示慢性肾脏疾病患者血管平滑肌细胞p53表达的抑制可能参与了血管钙化的发生机制。 Aim To determine the relationship between the expression of p53 protein in vascular smooth muscle cells ( VSMC ) and vascular calcification in maintenance hemodialysis patients with end-stage renal disease ( chronic kidney disease stage V ( CKD-V) ). Methods 17 maintenance hemodialysis patients with a autologous arteriovenous fistula ( AVF ) used for more than 1 year were referred for hemodialysis vascular acees reonstruction between July 2007 and July 2008, because of their primary AVF dysfunction. 17 artery segments ( HD group ) from dysfunctional AVF during the vascular aeees reconstruction and 8 abdominal aorta segments (control group) from cadaver kidney donors with the same age were collected as samples. Van Kossa histochemistry served as qualitative indicators of vascular calcification, cresolphthalein complexone chemical method served as quantification analysis of vascular calcification, and alkaline phosphatase (ALP) activity assay was performed following the assay kit. The expression of p53 protein in VSMC was analyzed by Western blotting, and the relationship between the expression of p53 protein in VSMC and vascular calcification in maintenance hemodialysis patients with CKD-V was analyzed. Results The expression of p53 protein ( p53/13-actin gray scale = 0.81 ) in HD group was significantly lower than that ( p53/β-actin gray scale = 1.72 ) in control group ( P 〈 0.01 ) , but 69% of the calcium contents and 105% of the ALP activity in HD group was increased compared with that in control group ( P 〈 0.01 ). The expression of p53 was negatively related to the calcium contents and the ALP activity in VSMC ( r = - 0.77 and r = - 0.86, P 〈 0.01 ). Conclusion Vascular calcification is extensively presented in maintenance hemodialysis patients with CKD-V, which is accompanied by the decreased expression of p53 in VSMC. This result implys that the expression inhibition of p53 in VSMC may be involved in the pathogenesis of vascular calcification.
出处 《中国动脉硬化杂志》 CAS CSCD 北大核心 2009年第1期31-34,共4页 Chinese Journal of Arteriosclerosis
基金 重庆市自然科学基金(CSTC 2008BB5275)
关键词 维持性血液透析 血管钙化 P53 碱性磷酸酶 血管平滑肌细胞 Maintenance Hemodialysis Vascular Calcification p53 Alkaline Phosphatase Vascular Smooth Muscle Cells
  • 相关文献

参考文献2

二级参考文献18

  • 1张宝红,姜智胜,齐永芬,庞永正,唐朝枢,杜军保.肾上腺髓质素对大鼠血管钙化的影响[J].中华老年多器官疾病杂志,2002,1(2):117-121. 被引量:7
  • 2张江蓉,王一尘,沈丽,卢维晟.复方丹参滴丸抑制血管异位钙化[J].中国动脉硬化杂志,2005,13(5):571-574. 被引量:14
  • 3Zoccali C, Mallarmaci F, Tripepi G. Novel cantiovascular risk factors in end- stage renal disease [ J ]. J Am Soc Nephrol, 2OO4,15 suppl 1:S77-80.
  • 4Collins A J, Li S, Ma JZ, Herzog C. Cardiovascular disease in end-stage renal disease patients [J]. Am J Kidney Dis 2001, 38 suppl 1: S26-29.
  • 5Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, el al. Coronary-artery calcification in young adults with end-stage renal diseases who are undergoing dialysis [J]. New England Jounal of Medicine, 2000, 342 ( 20 ) : 1 478-483.
  • 6Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease [ J ]. Nephrol Dial Transplant, 2000, 15 (7) : 1 014-021.
  • 7McCullough PA, Sandberg KR, Dumler F, Yanez JE. Determinants d coronay vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review [J]. J Nephrol, 2004, 17 (2) : 205-215.
  • 8O'rourke RA, Brundage BH, Froelicher VF, Creenland P, Grundy SM, Hachamovitch R,et al. American college of cardiology/American Heart Association Expert Conscnsus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease [ J ]. Circulation, 2000, 36 (1): 326-340.
  • 9Wong ND, Hsu JC, Detrano RC, Diamond G, Eisenberg H, Gardin JM.Coronary artery calcium evaluation by electron beam computed tomograhy and its relation to new cardiovascular evens [ J ]. Am J Cardiol, 2000, 86 (5): 495-498.
  • 10Reszka AA, Rodan GA. Mechanism of action of bisphosphonates [ J].Current Osteoprosis Reports, 2003, 1 (2) : 45-52.

共引文献17

同被引文献36

  • 1Schiffrin EL, Lipman ML, Mann JF. Chronic Kidney Disease: Effects on the Cardiovascular System. Circulation, 2007,116 (3) : 85 -97.
  • 2Wang A Y, Wang M, Woo J, et al. Cardiac : calcification as an important predictor for all cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients:a prospective study. J Am Soc Nephrol,2003,14 : 159-168.
  • 3Nakamura S, Ishibashi-Ueda H, Niizuma S, et al. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol, 2009,4 ( 12 ) : 1892 -900.
  • 4Fabbian F,De Giorgi A,Pala M. Evidence-based statin prescription for cardiovascular protection in renal impairment[J].Clinical and Experimental Nephrology,2011,(04):456-463.
  • 5Muntner P,He J,Astor BC. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease:results from the atherosclerosis risk in communities study[J].Journal of the American Society of Nephrology,2005,(02):529-538.
  • 6Thvendiranathen P,Bagai A,Brookhart MA. Primary prevention of cardiovascular diseases with statin therapy:a meta-analysis of randomized controlled trials[J].Archives of Internal Medicine,2006,(21):2307-2313.doi:10.1001/archinte.166.21.2307.
  • 7Chan KC,Wang CJ,Ho HH. Simvastatin inhibits cell cycle progression in glucose-stimulated proliferation of aortic vascular smooth muscle cells by up-regulating cyclin dependent kinase inhibitors and p53[J].Pharmacological Research,2008,(3-4):247-256.
  • 8Porter KE,Naik J,Turner NA. Simvastatin inhibits human saphenous vein neointima formation via inhibition of smooth muscle cell proliferation and migration[J].Journal of Vascular Surgery,2002,(01):150-157.
  • 9Agatston AS,Janowitz WR,Hildner FJ. Quantification of coronary artery calcium using ultrafast computed tomography[J].Journal of the American College of Cardiology,1990,(04):827-832.
  • 10Navaneethan SD,Hegbrant J,Strippoli GF. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease[J].Current Opinion in Nephrology and Hypertension,2011,(02):146-152.

引证文献4

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部